Molecular Biology of the Endothelin System
The endothelin system produces a diverse range of biologic effects in a variety of tissues throughout the body. Among its better-known effects is the regulation of both airway and blood vessel tone. Consisting of three ligands, two membrane-bound activating proteases, and two receptors (figure 1), this system has also been shown to have a significant effect on wound healing. All three of the ligands (endothelin-1 [EDN1, also known as ET-1], EDN2, and EDN3) are synthesized from a large precursor molecule, preproendothelin. These preproendothelins are processed by specific, furin-like proteases into biologically inactive 38-amino acid moieties, known as proendothelins or big endothelins. [1] Each of the three proendothelins (pro-EDN1, pro-EDN2, and pro-EDN3) is indiscriminately cleaved by one of two membrane-bound metalloproteinases, endothelin converting enzyme (ECE)-1 or -2, to produce its corresponding 21-amino acid, metabolically active endothelin peptide. [2, 3] Both ECE-1 and -2 preferentially cleave pro-EDN1, the most abundant of the three endothelins, whose levels are highest in the lung. EDN2 and EDN3 are expressed by intestinal epithelial cells, while EDN3 is also expressed by brain neurons and renal tubular cells. [4, 5] In the lung, fibroblasts, endothelial cells, alveolar macrophages, epithelial cells, and polymorphonuclear leukocytes all secrete EDN1. [6] [7] [8] [9] EDN1 is not stored. Its regulation takes place at the level of gene expression and protein synthesis, both of which can be affected by a host of factors, including angiotensin II and thrombin, as well as mechanical factors such as shear stress. [3] Eighty percent of EDN1 synthesized in lung endothelial or epithelial cells is transported to the basolateral cell pole via intracellular vesicles [10] and secreted through the basolateral membrane. Here, it acts on nearby smooth muscle cells and other interstitial constituents via autocrine and paracrine mechanisms. [1, 3, 11] Not surprisingly, concentrations of EDN1 within vessel walls are >100 times their concentrations within the plasma. [2] While peptide secreted into vessel lumens can act at distant sites as a hormone, under normal conditions, EDN1 plasma concentrations are two orders of magnitude below the pharmacologic threshold. [2] There are three endothelin-specific receptors, but only two (EDNRA and EDNRB, also known as ET A and ET B ) have been cloned in humans. [12, 13] EDN1 has greater affinity for EDNRA than do the other two endothelins, while each of the ligands has equal affinity for EDNRB. These receptors are located on a number of cell types and in a variety of organ systems throughout the body, including the pulmonary, nervous, cardiovascular, renal, and integumentary systems. In the lung, EDNRA receptors are found in greatest quantities on vascular and airway smooth muscle cells; EDNRB receptors are also found on smooth muscle cells but are predominantly located on endothelial cells, where EDNRA is not expressed. [2, [12] [13] [14] [15] In human bronchi, there are ten times more EDNRB receptors than EDNRA receptors. [16, 17] The initial, short-term response to an intravenous bolus of EDN1 is a decrease in vascular resistance, primarily mediated by the release of nitric oxide and prostacyclin from EDNRBstimulated endothelial cells. [18, 19] A subsequent and longerlived (up to an hour) increase in vascular resistance is mediated via EDNRA stimulation of vascular smooth muscle cells. [20] Aside from its other activities, EDNRB also acts as a scavenger receptor, mediating EDN1 clearance from the circulation, primarily in the lung and, to a lesser degree, in the liver and kidney. [21] 2. Normal Wound Healing, Fibrosis, and Endothelin-1 (EDN1)
Normal wound healing involves a complex series of structural and biochemical events that give rise to new epithelium, blood vessels, and connective tissue. [22] Study of these events in skin has yielded extensive information on normal healing, which is described as occurring in three main phases: inflammation, proliferation, and matrix formation with remodeling. [23] In one of the earliest events in the inflammatory phase, the coagulation system is activated. Later in the inflammatory phase, macrophages take on a key role, synthesizing and releasing regulatory and growth factors. [24, 25] One of the key occurrences in normal wound healing, whether in the lung, skin, or any other organ, is fibroblast migration into the wound bed. Once there, fibroblasts are driven to proliferate and express a-smooth muscle actin, a key property of the myofibroblast phenotype. Fibroblasts, myofibroblasts, endothelial cells, macrophages, and other cells proliferate and embed themselves in a collection of collagen, fibrin, fibronectin, proteoglycans, and other molecules, which collectively comprise granulation tissue. Fibroblasts and myofibroblasts within the granulation tissue secrete extracellular matrix (ECM), which consists of numerous components, including various proteins -of which collagen is the most abundant. The ECM provides attachment sites for cell surface receptors and serves as a reservoir for signaling factors. The ECM also gives healing tissue structural support; [26] it has been called ''nature's natural scaffold fory tissue reconstruction following injury'' [26] (figure 2). Granulation tissue constituents are extremely metabolically active, and adequate blood flow is needed to support it. Thus, in conjunction with ECM formation, angiogenesis -the process of new blood vessel formation -occurs in this new tissue proliferation phase.
Through its contractile properties, the myofibroblast is primarily responsible for remodeling the ECM and giving it tensile strength. [28] In normal wound healing, once the ECM is restored and remodeled appropriately, fibroblasts and myofibroblasts are downregulated, cease collagen production, and undergo apoptosis; sound organ function then returns. [29] During the inflammatory phase, through its effects on various cells, EDN1 is involved in normal wound healing: EDN1 can prime neutrophils [30] and stimulate monocytes to produce a number of cytokines. [31] Endothelin-1 also plays a role in the later phases of healing by stimulating fibroblast chemotaxis, [32, 33] proliferation, [34] and procollagen formation. [35, 36] Accumulating evidence suggests that EDN1 is active in fibrogenesis. Although detailed descriptions of the intracellular mechanisms through which EDN1 mediates pro-fibrotic actions are beyond the scope of this review, some of the ways in which EDN1 participates in fibrogenesis are highlighted here. For example, one of the key features of fibrogenesis is abnormal persistence of the myofibroblast phenotype in healing tissue, which leads to high levels of matrix constituents (particularly collagen), exuberant ECM contraction, and ultimately, scar formation. [37] EDN1 is one molecule that can induce resistance to apoptosis in lung fibroblasts -a process carried out via the pro-survival PI3 AKT signaling pathway. [38] In certain tissues, EDN1 enhances the expression of the profibrotic moieties, fibronectin and connective tissue growth factor, and it reduces collagenase activity. [27] EDN1 can act synergistically with a number of molecules known to be important in fibrogenesis, including transforming growth factor-b (TGF-b), basic fibroblast growth factor, and platelet-derived growth factor to induce cellular transformation or replication. [3] For example, in endothelial cells, the potent fibrogenic cytokine TGF-b induces EDN1 gene expression and protein release via direct transcriptional regulation of the EDN1 gene promoter. [39] In cultured human lung fibroblasts, EDN1 induces expression of the myofibroblast phenotype -the collagen-producing machinery in idiopathic pulmonary fibrosis (IPF) [27, 32] -effects that appear to be dependent on EDNRA but not EDNRB. [27] 3. The Role of EDN1 in Lung Fibrosis: Animal Models Several investigators have examined the impact of the endothelin system on lung fibrosis. Transgenic mice with lungspecific overexpression of the human gene for EDN1 spontaneously develop chronic lung inflammation and fibrosis, and they develop perivascular and peribronchiolar accumulations of extracellular matrix proteins and large collections of CD4+ mononuclear cells. Interestingly, pulmonary hypertension does not develop. [40] Results of endothelin receptor antagonism on lung fibrosis have been contradictory. For example, Park and colleagues [41] found that both EDN1 and ECE-1 immunoreactivity are increased in a rat model of bleomycin-induced pulmonary fibrosis and that a non-selective endothelin receptor antagonist reduced the amount of fibrosis. In contrast, Mutsaers and co-investigators [42] found that neither an EDNRA selective nor a non-selective endothelin receptor antagonist altered bleomycininduced collagen deposition in the rat.
The Role of EDN1 in Lung Fibrosis: Human Data
The precise pathobiology of progressive lung fibrosis is unknown. The current hypothesis proposed for the development and progression of IPF is that it is an 'epithelial-fibroblastic' disease. [43] In this model, injured alveolar epithelial cells orchestrate the development of an actively profibrotic environment by producing pro-fibrotic cytokines such as TGF-b, tumor necrosis factor-a (TNFa), and EDN1. Within this environment, fibroblasts are chronically activated, resulting in the development of myofibroblasts, excessive production of collagen and ECM, and dysregulated tissue repair. [44] A number of studies have evaluated the role of EDN1 in human pulmonary fibrosis. Additional data from studies examining biologic samples from subjects with scleroderma (SSc) and scleroderma-associated interstitial lung disease (SSc-ILD) also exist. In fact, the first clinical evidence suggesting that EDN1 played an important role in tissue fibrosis came from patients with SSc. [45] In these patients, EDN1 expression is increased in the skin [46] and lung. [47] Although most patients with SSc-ILD have a nonspecific interstitial pneumonia (NSIP) rather than usual interstitial pneumonia (UIP) pathologic pattern of lung injury (the pathologic correlate of IPF), data from these patients provide potentially important Fig. 2 . Role of the endothelin system in extracellular matrix contraction (reproduced from Shi-Wen et al., [27] with permission). ECM = extracellular matrix; EDN1 = endothelin-1; EDNRA = endothelin receptor A; m indicates increased activity.
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insights into the role of EDN1 in fibrotic lung disease, including IPF.
In patients with SSc-ILD, EDN1 levels are increased in bronchoalveolar lavage (BAL) fluid, [47] and nearly half of the fibroblast mitogenic activity of the BAL fluid in these patients is due to EDN1. [34] Increased levels of EDN1, when compared with levels in healthy controls, are also found in the exhaled breath condensate of subjects with either idiopathic NSIP or SSc-ILD. [48] Furthermore, EDN1 expression is increased in the lungs of subjects with SSc and related pulmonary fibrosis but without clinical evidence of pulmonary hypertension; while EDN1 expression is absent in normal control lung. [34] Shi-Wen and colleagues [27] showed that fibroblasts cultured from the explanted lungs of SSc-ILD patients had enhanced EDN1 expression and that expression of a-smooth muscle actin (and other contractile proteins) could be reduced by antagonizing endogenous EDN1 signaling.
In IPF, preproendothelin-1 messenger RNA is elevated in airway epithelial cells, proliferating type II pneumocytes, endothelial cells, and inflammatory cells. [49, 50] Alveolar macrophages recovered by BAL from patients with IPF spontaneously express EDN1, while those from controls do not; [32] in addition, plasma levels of EDN1 are significantly higher in patients with IPF than in normal controls. [51] In certain diseases (e.g. connective tissue disease), endothelial cell injury may be among the earliest events, preceding inflammation or fibrosis. It has been suggested that, in these diseases, endothelial cell injury could lead to EDN1 release into the bloodstream and result in the generation of endothelininitiated inflammatory and fibrotic cascades. [45] Lending some support to this hypothesis is the finding that, in subjects with mixed connective tissue disease, plasma levels of antiendothelial cell antibodies correlate with plasma levels of EDN1. [19] Whether this occurs in IPF is unknown. Finally, while the results of a prospective, placebocontrolled study investigating the efficacy of dual endothelin receptor antagonism in SSc-ILD were negative, [52] more encouraging results are available from a recently completed trial in IPF. In the international, double-blind, placebocontrolled trial (BUILD-1; Bosentan Use in Interstitial Lung Disease) of the nonselective endothelin-receptor antagonist bosentan, analyses suggested that endothelin antagonism may be beneficial in a subgroup of patients with IPF. [53] There was no difference between the placebo or bosentan groups in the primary endpoint of change from baseline in distance walked during a 6-minute walk test (mean 18 m less in the bosentantreated group). There was a trend favoring bosentan in the secondary combined endpoint of time to disease progression or death (p = 0.1). Among subjects who underwent surgical lung biopsy as part of their diagnostic evaluation, bosentan was associated with a significantly decreased risk of worsening pulmonary function (relative risk 0.32 with upper limit of 95% CI = 0.75) and delayed time to disease progression or death (p = 0.009). Because current practice is to perform surgical lung biopsy in a patient whose high-resolution CT (HRCT) scan does not show findings considered classic for an underlying pathologic pattern of UIP, data from BUILD-1 suggest that bosentan may be effective in subjects with atypical HRCT scans (e.g. scans that have little or no honeycombing) -in many cases, it is believed that HRCT patterns atypical for UIP correspond to earlier or less severe disease. Whatever the case, these results have provided the impetus for a second, larger, multicenter study (BUILD-3) whose results are eagerly awaited.
Other trials registered on www.clinicaltrials.gov in which investigators will test the effectiveness of endothelin antagonists in patient with IPF include the ARTEMIS trial (Randomized, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of Ambrisentan in IPF) sponsored by Gilead Sciences, two studies examining the effectiveness of bosentan in patients with pulmonary hypertension in the setting of IPF (one in the US, and one in the UK) -both sponsored in part by Actelion Pharmaceuticals, and at least two other trials (specifics not yet made public) of endothelin antagonists in IPF.
Conclusions
Data from basic science, animal, and translational studies support the idea that the endothelin system, and EDN1 in particular, plays a role in the pathogenesis of IPF. While the initial data regarding a potential benefit of dual endothelin receptor antagonism in some patients with IPF are encouraging, additional investigation is necessary -and underway -to determine how to treat this challenging and devastating disease.
